GlassScriptPhysician profile
Esther E Digiacomo
NPI 1295972180
$2,861.78
in general payments reported to CMS, 2019-2025
44 companies · $857 in 2025
The $857 reported for 2025 was more than what 88% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $224 · 2022: $354 · 2023: $430 · 2024: $996 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,283.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $774.16 | 2021-2025 | Proclaim, Eterna |
| Abbvie INC. | $180.86 | 2023-2025 | |
| Averitas Pharma INC. | $136.29 | 2023-2025 | Qutenza |
| Boston Scientific Corporation | $132.21 | 2021-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Lundbeck LLC | $107.43 | 2022-2024 | Vyepti |
| Genentech USA, INC. | $104.16 | 2023-2024 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Sk Life Science, INC. | $102.70 | 2023-2025 | |
| Emd Serono, INC. | $89.83 | 2022-2023 | Mavenclad |
| Csl Behring | $81.29 | 2025 | Hizentra |
| Biogen, INC. | $80.21 | 2021-2024 | Tysabri, Vumerity |
| Alexion Pharmaceuticals, INC. | $74.91 | 2022-2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $67.34 | 2024-2025 | Austedo Xr, Austedo Xr |
| Relievant Medsystems, INC. | $65.70 | 2022-2023 | Intracept |
| Ucb, INC. | $65.19 | 2022-2025 | Nayzilam |
| Ani Pharmaceuticals, INC. | $64.79 | 2023-2024 | Purified Cortrophin Gel |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esther Digiacomo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.